ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Leap Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-6.37%
EBIT to Interest (avg)
-56.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.54
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.84%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.38
EV to EBIT
-1.23
EV to EBITDA
-1.23
EV to Capital Employed
0.32
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.16%
ROE (Latest)
-23.06%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -32.86 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
PRE-TAX PROFIT(Q)
At USD -4.73 MM has Grown at 69.36%
NET PROFIT(Q)
Highest at USD 0.39 MM
-9What is not working for the Company
INTEREST(HY)
At USD 0.01 MM has Grown at 33.33%
CASH AND EQV(HY)
Lowest at USD 20.72 MM
DEBT-EQUITY RATIO
(HY)
Highest at -7.88 %
EPS(Q)
Lowest at USD -0.46
Here's what is working for Leap Therapeutics, Inc.
Net Profit
At USD 0.39 MM has Grown at 102.52%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -32.86 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -4.73 MM has Grown at 69.36%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 0.39 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Leap Therapeutics, Inc.
Interest
At USD 0.01 MM has Grown at 33.33%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
EPS
Lowest at USD -0.46
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Cash and Eqv
Lowest at USD 20.72 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -7.88 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
